Ponatinib vs. asciminib in post–second-generation tyrosine kinase inhibitor therapy for chronic-phase chronic myeloid leukemia: a matching-adjusted indirect comparison

Ponatinib vs. asciminib in post–second-generation tyrosine kinase inhibitor therapy for chronic-phase chronic myeloid leukemia: a matching-adjusted indirect comparison

BackgroundPonatinib and asciminib are approved for third-line therapy in chronic-phase chronic myeloid leukemia (CP-CML) and are the only drugs approved for patients with the T315I mutation in the United States. In Europe, only ponatinib is approved for patients with the T315I mutation.MethodsClinic...

Full description

Saved in:
Bibliographic Details
Main Authors: Valentin Garcia-Gutierrez, Fei Huang, Ajibade Ashaye, Mehul Dalal, Victor Laliman-Khara, Massimo Breccia, Megan Rutherford, Hoora Moradian, Petros Patos, Elias Joseph Jabbour
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-11-01
Series:Frontiers in Oncology
Subjects:
chronic myeloid leukemia
ponatinib
asciminib
T315I mutation
BCR::ABL1 (BCR-ABL1)
major molecular response
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2024.1455378/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2024.1455378/full

Similar Items